๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› France
Clinical trial register · European Union · CTIS

Clinical Trials in France

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 21 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524 Belgium 426 Czechia 327
All 28 states
85 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I/II
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
2024-520238-31-01Advanced Lung Cancer
BioNTech SE
Neoplasms
Spain, France, Italy, Poland
24/02/2026
Phase I/II
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
2022-502911-12-00Propionic Acidemia
Moderna Inc.
Nutritional and Metabolic Diseases
Spain, Netherlands, France
23/02/2026
Phase I/II
A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults with Chronic Hepatitis B
2025-523619-12-00Chronic Hepatitis B
Nchroma Bio Inc.
Virus Diseases
France
20/02/2026
Phase I/II
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
2025-521164-36-00Patients with relapsed/refractory advanced/metastatic ovariโ€ฆ
Apmonia Therapeutics
Neoplasms
Belgium, France
19/02/2026
Phase I/II
Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease
2024-519412-13-00Canavan Disease, Canavan disease
Myrtelle Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
18/02/2026
Phase I/II
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
2025-522595-87-00Hematological Malignancies
Daiichi Sankyo Inc.
Neoplasms
France, Italy
16/02/2026
Phase I/II
A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
2025-521671-31-00Relapsed/Refractory (R/R) and Minimal Residual Disease Posiโ€ฆ
Amgen Inc.
Neoplasms
France, Netherlands, Italy
13/02/2026
Phase I/II
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants with Invasive Ventilator-dependent X-linked Myotubular Myopathy
2025-523213-29-00X-linked myotubular myopathy
Astellas Gene Therapies Inc.
Musculoskeletal Diseases
France
09/02/2026
Phase I/II
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
2024-519881-32-00Sickle Cell Disease
Novo Nordisk A/S
Hemic and Lymphatic Diseases
France
06/02/2026
Phase I/II
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04โ€“Substudy 04D
2025-522253-19-00Urothelial carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Netherlands, France, Spain
03/02/2026
Phase I/II
Evaluation of a [68Ga] Ga-HER2 single domain antibody PET/CT for predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in HER2-positive early breast cancer
2025-523286-23-00Breast Cancer
Centre Henri Becquerel
Not possible to specify
France
26/01/2026
Phase I/II
A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME
2025-521973-16-00Netherton Syndrome
Biocryst Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
France, Netherlands, Germany
20/01/2026
Phase I/II
DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional ฮฒAS3m/miR7m lentiviral vector expressing the ฮฒAS3m and a micro-RNA (miRNA) targeting specifically the endogenous ฮฒS-globin mRNA in Patients with Sickle Cell Disease (SCD)
2025-521257-17-00SCD severe patients
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
16/01/2026
Phase I/II
A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer
2025-523273-41-00Metastatic castration-resistant prostate cancer
T.O.A.D. Oncology S.A.
Neoplasms
Spain, France
16/01/2026
Phase I/II
A Phase 1/2, multicentre, open-label clinical trial of DT-7012 as monotherapy and in combination with an immune checkpoint inhibitor in participants with selected advanced solid tumours
2025-523758-15-00Cancer
Domain Therapeutics Australia Pty Limited
Neoplasms
France
14/01/2026
Phase I/II
An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants with Locally Advanced or Metastatic Solid Tumours.
2025-522139-33-00Advanced or metastatic solid tumours
Ipsen Pharma
Neoplasms
France, Spain
23/12/2025
Phase I/II
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naรฏve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with cโ€ฆ
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France
22/12/2025
Phase I/II
TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer
2025-521873-15-00Metastatic hormone-sensitive prostate cancer
Novartis Pharma AG
Neoplasms
Hungary, Spain, Italy, Germany, France
18/12/2025
Phase I/II
An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies
2025-522184-15-00Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen Pharma
Neoplasms
Spain, France
16/12/2025
Phase I/II
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer
2025-521880-10-00Metastatic castrate resistant prostate cancer (mCRPC)
Novartis Pharma AG
Neoplasms
Italy, Germany, Poland, France, Denmark, Spain
01/12/2025
Phase I/II
InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2 part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN 6400 in Adult Patients with Hereditary Hemorrhagic Telangiectasia (HHT)
2025-522510-23-00Hereditary Hemorrhagic Telangiectasia (HHT)
Alnylam Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Spain, Germany
26/11/2025
Phase I/II
A Phase Ib/ II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Have Previously Progressed During or After a CDK4/6 Inhibitor
2025-521128-31-00Locally Advanced or Metastatic Estrogen Receptor-Positive, โ€ฆ
Genentech Inc.
Neoplasms
Spain, Italy, France, Germany
26/11/2025
Phase I/II
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
2025-521672-60-00Metastatic or locally advanced SST2-positive neuroendocrineโ€ฆ
Crinetics Pharmaceuticals Inc.
Neoplasms
Spain, France, Germany, Italy
21/11/2025
Phase I/II
Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors
2025-521828-30-00Advanced Solid Tumors
Pyxis Oncology Inc.
Neoplasms
France, Spain, Poland
19/11/2025
Phase I/II
A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors
2025-521441-24-00Advanced or Metastatic Solid Tumors
Alentis Therapeutics AG
Neoplasms
Spain, France, Netherlands, Italy
12/11/2025
Rows per page Showing 51–75 of 85
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-europe/country/france

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.